A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

NCT04813796 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2

Interventions

BIOLOGICAL: mRNA-1283
BIOLOGICAL: mRNA-1273
BIOLOGICAL: Placebo

Sponsor

ModernaTX, Inc.